Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 8 results
Author [ Title(Desc)] Type Year
Filters: First Letter Of Title is R  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
R
Lewis JD, Sandler RS, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF et al..  2021.  A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.. Gastroenterology. 161(3):837-852.e9.
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P.  2008.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.. Gastroenterology. 135(4):1130-41.
Longman RS, Moreira RK, Littman DR, Green PHR, Sethi A.  2012.  A rare intestinal infection with systemic effects.. Gastroenterol Hepatol (N Y). 8(1):60-3.
J Blander M, Longman RS, Iliev ID, Sonnenberg GF, Artis D.  2017.  Regulation of inflammation by microbiota interactions with the host.. Nat Immunol. 18(8):851-860.
Scherl EJ, Kumar S, Warren RU.  2010.  Review of the safety and efficacy of ustekinumab.. Therap Adv Gastroenterol. 3(5):321-8.
Dogan B, Fu J, Zhang S, Scherl EJ, Simpson KW.  2018.  Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses.. J Antibiot (Tokyo). 71(5):485-494.
Kothary V, Scherl EJ, Bosworth B, Jiang Z-D, Dupont HL, Harel J, Simpson KW, Dogan B.  2013.  Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.. Antimicrob Agents Chemother. 57(2):811-7.
Cohen-Mekelburg S, Schneider Y, Gold S, Ghosh G, Rosenblatt R, Hajifathalian K, Scherl E, Schnoll-Sussman F, Katz P, Steinlauf A.  2019.  Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care.. Dig Dis Sci. 64(8):2273-2279.